Search clinical trials for: DLCL

Total 6 results

Institute of Hematology & Blood Diseases Hospital

Recruiting

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma

China
Weill Medical College of Cornell University

Completed

Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET)

Diffuse Large B-cell Lymphoma

United States
Susan Knox
GlaxoSmithKline; Corixa Corporation

Completed

Phase 2 Study of Bexxar in Relapsed/Refractory DLCL

Lymphoma

United States
Rigel Pharmaceuticals

Completed

Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma

Lymphoma

United States
David Rizzieri, MD
Novartis Pharmaceuticals

Terminated

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma (DLCL04)

Diffuse Large B-Cell Lymphoma | IPI≥2

Italy

3

Subscribe